# Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

> **NCT05175950** · PHASE2 · UNKNOWN · sponsor: **Korea University Guro Hospital** · enrollment: 770 (estimated)

## Conditions studied

- COVID-19 (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
- **OTHER:** Normal saline

## Key facts

- **NCT ID:** NCT05175950
- **Lead sponsor:** Korea University Guro Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-24
- **Primary completion:** 2023-08
- **Final completion:** 2023-11
- **Target enrollment:** 770 (ESTIMATED)
- **Last updated:** 2023-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05175950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05175950, "Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05175950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*